title: Progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy.
abstract: The prognosis of patients with progressive intermediate-grade non-Hodgkin's lymphoma (NHL) after high-dose chemotherapy and autologous peripheral stem-cell transplantation (PSCT) is poor, with survival measured in months. The advent of monoclonal antibody therapy for NHL has created new options for effective therapy with relatively mild side effects. We report on two patients with progressive intermediate-grade NHL after PSCT who were treated with monoclonal antibody therapy. Both patients initially received rituximab (unlabeled anti-CD20 monoclonal antibody) and were subsequently treated with (90)Y-epratuzumab (yttrium-90-labeled humanized anti-CD22 monoclonal antibody) at relapse. One patient received (90)Y-epratuzumab alone while the other was treated with higher doses in combination with autologous peripheral stem-cell infusion. Both patients achieved a rapid response to the radiolabeled antibody with minimal toxicity. Monoclonal antibody therapy may be an effective and tolerable treatment for progressive NHL after PSCT.
authors.affiliation: Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA. detsai@mail.med.upenn.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Tsai
authors.forename: S J
authors.initials: SJ
authors.lastname: Schuster
authors.forename: A
authors.initials: A
authors.lastname: Matthies
authors.forename: H C
authors.initials: HC
authors.lastname: Moore
authors.forename: A
authors.initials: A
authors.lastname: Alavi
authors.forename: M E
authors.initials: ME
authors.lastname: Juweid
authors.forename: D M
authors.initials: DM
authors.lastname: Goldenberg
authors.forename: E A
authors.initials: EA
authors.lastname: Stadtmauer
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001402:B-Lymphocytes / Q000276:immunology; D001772:Blood Cell Count; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009333:Neck / Q000000981:diagnostic imaging; D011859:Radiography; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D000970:Antineoplastic Agents